Literature DB >> 26323923

Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.

Yong Cui, Chang Dong1, Bing-Qun Wu, Xin-Chun Duan, Guan Shi, Min Gong, Tian-You Wang.   

Abstract

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a frequently occurring cancer with poor prognosis despite combined therapeutic strategies. The aim of the current study was to elucidate a further finding on the clinicopathologic significance of immunohistochemical expression of cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR) in Chinese patients with ESCC.
METHODS: Formalin-fixed paraffin-embedded surgically resected tumor samples were obtained from 140 randomly selected Chinese patients with ESCC. Sections were immunohistochemically stained for COX-2, VEGF, and EGFR. The correlations between clinicopathological features and the high expression of COX-2, VEGF, and EGFR were analyzed using the Statistical Package for the Social Sciences 19.0 software (IBM Inc., Chicago, IL, USA).
RESULTS: In the present study, high expression of COX-2, EGFR, and VEGF was found in 64.3%, 62.1%, and 65.0%, respectively. Results showed that COX-2 overexpression was significantly correlated with degree of differentiation (P = 0.000), and lymph node metastasis (negative/positive, P = 0.002). EGFR and VEGF overexpression was significantly correlated with a differentiated degree, T stage, N stage, and tumor, node, metastases stage.
CONCLUSION: High expression of COX-2, EGFR, and VEGF is an unfavorable prognostic factor in ESCC, and could be used as a poor prognosis indicator for the ESCC patients. Targeting therapy to these three targets should be considered to the combined treatment in ESCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26323923     DOI: 10.4103/0973-1482.163838

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  5 in total

1.  CCR7 enhances the angiogenic capacity of esophageal squamous carcinoma cells in vitro via activation of the NF-κB/VEGF signaling pathway.

Authors:  Qing-Yong Cai; Gui-You Liang; Yi-Feng Zheng; Qun-You Tan; Ru-Wen Wang; Kun Li
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Krt5+/Krt15+ foregut basal progenitors give rise to cyclooxygenase-2-dependent tumours in response to gastric acid stress.

Authors:  Hyeongsun Moon; Jerry Zhu; Leanne R Donahue; Eunju Choi; Andrew C White
Journal:  Nat Commun       Date:  2019-05-20       Impact factor: 14.919

3.  Expression analysis of cyclooxygenase-2 in patients suffering from esophageal squamous cell carcinoma.

Authors:  Shahida Tasneem; Muhammad Tahir Sarwar; Muhammad Rizwan Bashir; Hamid Hussain; Jawad Ahmed; Shahid Pervez
Journal:  PLoS One       Date:  2018-10-19       Impact factor: 3.240

4.  GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.

Authors:  Jiang Pi; Jinhuan Jiang; Huaihong Cai; Fen Yang; Hua Jin; Peihui Yang; Jiye Cai; Zheng W Chen
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.

Authors:  Congying Xie; Zhao Jing; Honglei Luo; Wei Jiang; Li Ma; Wei Hu; Anping Zheng; Duojie Li; Lingyu Ding; Hongyan Zhang; Conghua Xie; Xilong Lian; Dexi Du; Ming Chen; Xiuhua Bian; Bangxian Tan; Bing Xia; Ruifei Xie; Qing Liu; Lvhua Wang; Shixiu Wu
Journal:  Br J Cancer       Date:  2020-09-22       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.